Company Interview / Orthocell (ASX: OCC) Investor Presentation

Paul Anderson, CEO and co-founder of Orthocell (ASX:OCC) talks about developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include Striate, SmrtGraft and Remplir for peripheral nerve reconstruction, which was approved for in the US, with the Company appointing distributors, with sales expected to follow shortly.

The global addressable market for Remplir is rapidly expanding, with Orthocell having just been granted a Medical Device Licence by Health Canada to allow its sale.

Listen to the interview to hear more about Paul's ambitions on US market expansion and for why Remplir has the potential to outperform competitors is amplified by its unique design, promising improved surgical outcomes and economic benefits.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD